Company intelligence / Profile preview

Center for Breakthrough Medicines

King of Prussia / Philadelphia area, Pennsylvania, United Statescbm-global.org ↗

Ownership: Private
Employees: ~379
Development stage: Commercial

Overview

Center for Breakthrough Medicines is one of the world’s largest single-site cell and gene therapy CDMOs. It offers end-to-end services from process development through commercial-scale GMP manufacturing, including plasmid DNA production, viral vector manufacturing, cell banking/processing, testing/analytics, and fill-finish. The company has rapidly expanded capacity to meet global demand in advanced therapies. In 2023 SK pharmteco acquired controlling interest in CBM to create an integrated global CGT business unit.

Modalities: Cell therapyGene therapyPlasmid DNA productionViral vector manufacturing
Industry: Contract Manufacturing Organization

Partnerships

YposkesiAMPAC Fine Chemical

Beyond the preview

Go deeper on Center for Breakthrough Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Center for Breakthrough Medicines.

Explore the full profile